Literature DB >> 17721681

Utility of a rapid diagnosis kit for Mycoplasma pneumoniae pneumonia in children, and the antimicrobial susceptibility of the isolates.

Takao Ozaki1, Naoko Nishimura, Jaekun Ahn, Naoko Watanabe, Taichiro Muto, Akiko Saito, Norio Koyama, Kazumasa Nakane, Keiji Funahashi.   

Abstract

We evaluated a kit for the rapid diagnosis of Mycoplasma pneumoniae infection and investigated the antimicrobial susceptibility of the isolates. A total of 194 otherwise healthy children, aged 0.3-14.9 years, were diagnosed as having pneumonia by chest X-ray findings between December 2003 and November 2004, and were admitted to Showa Hospital. Isolation of M. pneumoniae was attempted from a throat swab obtained on admission, and the complement fixation titer was measured in paired serum samples obtained at admission and at the convalescent stage. We also used a rapid diagnosis kit (ImmunoCard Mycoplasma) for the detection of specific immunoglobulin M antibody in paired sera. Pneumonia due to M. pneumoniae was defined by isolation of this microorganism, or by seroconversion, or a >or=4-fold increase in the antibody titer. Using each isolate, we determined the minimum inhibitory concentrations for five antimicrobial agents by the broth dilution method. M. pneumoniae pneumonia was diagnosed in 45 children (23.2%). The ImmunoCard had a sensitivity of 31.8% using admission serum and 88.6% using paired sera, while the specificity was 78.1% and 70.5%, respectively. M. pneumoniae was isolated from 14 of the 45 patients (31.1%). The 50%/90% minimum inhibitory concentration (microg/ml) of erythromycin, clarithromycin, azithromycin, minocycline, and levofloxacin was 0.006/0.012, <or=0.003/<or=0.003, <or=0.003/<or=0.003, 0.78/1.56, and 0.39/0.78, respectively. For a rapid diagnosis of M. pneumoniae pneumonia, the ImmunoCard was not effective. Macrolides showed superior in vitro antimicrobial activity against M. pneumoniae isolates causing pediatric pneumonia.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17721681     DOI: 10.1007/s10156-007-0519-6

Source DB:  PubMed          Journal:  J Infect Chemother        ISSN: 1341-321X            Impact factor:   2.211


  13 in total

Review 1.  Mycoplasma pneumoniae from the Respiratory Tract and Beyond.

Authors:  Ken B Waites; Li Xiao; Yang Liu; Mitchell F Balish; T Prescott Atkinson
Journal:  Clin Microbiol Rev       Date:  2017-07       Impact factor: 26.132

2.  Microfluidic platform versus conventional real-time polymerase chain reaction for the detection of Mycoplasma pneumoniae in respiratory specimens.

Authors:  Elizabeth Wulff-Burchfield; Wiley A Schell; Allen E Eckhardt; Michael G Pollack; Zhishan Hua; Jeremy L Rouse; Vamsee K Pamula; Vijay Srinivasan; Jonathan L Benton; Barbara D Alexander; David A Wilfret; Monica Kraft; Charles B Cairns; John R Perfect; Thomas G Mitchell
Journal:  Diagn Microbiol Infect Dis       Date:  2010-03-12       Impact factor: 2.803

3.  Clinical potential of diagnostic methods for the rapid diagnosis of Mycoplasma pneumoniae pneumonia in adults.

Authors:  N Miyashita; Y Kawai; T Yamaguchi; K Ouchi; M Oka
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2011-03       Impact factor: 3.267

Review 4.  New insights into the pathogenesis and detection of Mycoplasma pneumoniae infections.

Authors:  Ken B Waites; Mitchell F Balish; T Prescott Atkinson
Journal:  Future Microbiol       Date:  2008-12       Impact factor: 3.165

5.  Difference of clinical features in childhood Mycoplasma pneumoniae pneumonia.

Authors:  You-Sook Youn; Kyung-Yil Lee; Ja-Young Hwang; Jung-Woo Rhim; Jin-Han Kang; Joon-Sung Lee; Ji-Chang Kim
Journal:  BMC Pediatr       Date:  2010-07-06       Impact factor: 2.125

Review 6.  Mycoplasma pneumoniae-associated mild encephalitis/encephalopathy with a reversible splenial lesion: report of two pediatric cases and a comprehensive literature review.

Authors:  Norishi Ueda; Satoshi Minami; Manabu Akimoto
Journal:  BMC Infect Dis       Date:  2016-11-11       Impact factor: 3.090

7.  A sensitive and rapid immunoassay for Mycoplasma pneumoniae in children with pneumonia based on single-walled carbon nanotubes.

Authors:  Ming Song; Ying Zhang; Shi Li; Chunsheng Zhang; Mingming Tao; Ying Tang; Zhuquan Jiang; Sulan Cai; Wei Xu; Weizhuo Xu
Journal:  Sci Rep       Date:  2017-11-27       Impact factor: 4.379

8.  A comparison study between GeXP-based multiplex-PCR and serology assay for Mycoplasma pneumoniae detection in children with community acquired pneumonia.

Authors:  Le Wang; Zhishan Feng; Mengchuan Zhao; Shuo Yang; Xiaotong Yan; Weiwei Guo; Zhongren Shi; Guixia Li
Journal:  BMC Infect Dis       Date:  2017-07-25       Impact factor: 3.090

9.  Prescription surveillance and polymerase chain reaction testing to identify pathogens during outbreaks of infection.

Authors:  Hiroaki Sugiura; Tsuguto Fujimoto; Tamie Sugawara; Nozomu Hanaoka; Masami Konagaya; Kiyoshi Kikuchi; Eisuke Hanada; Nobuhiko Okabe; Yasushi Ohkusa
Journal:  Biomed Res Int       Date:  2013-02-07       Impact factor: 3.411

10.  Antibody responses to Mycoplasma pneumoniae: role in pathogenesis and diagnosis of encephalitis?

Authors:  Patrick M Meyer Sauteur; Bart C Jacobs; Emiel B M Spuesens; Enno Jacobs; David Nadal; Cornelis Vink; Annemarie M C van Rossum
Journal:  PLoS Pathog       Date:  2014-06-12       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.